{"id":"W4225291722","doi":"10.1016/j.ejca.2022.03.029","title":"Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Avelumab; Neuroendocrine tumors; Internal medicine; Gastroenterology; Progressive disease; Oncology; Surgery; Clinical trial; Chemotherapy; Immunotherapy; Cancer; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00193042,0.0003495233,0.001213835,0.0005598028,0.0001791293,0.0001009177,0.0004635531,0.000003432551,0.001170323],"category_scores_gemma":[0.003063152,0.0002850413,0.0001843907,0.0006361984,0.0001841467,0.0002824369,0.0004202369,0.001502764,0.00001138975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001810207,"about_ca_system_score_gemma":0.0003578502,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000218979,"about_ca_topic_score_gemma":0.00006877448,"domain_scores_codex":[0.9918061,0.003650698,0.001909941,0.0005097239,0.001397715,0.0007258316],"domain_scores_gemma":[0.9963248,0.001179243,0.00130092,0.0004174823,0.000257151,0.000520349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"not_applicable","study_design_scores_codex":[0.08749457,0.002642192,0.01751547,0.0003111418,0.001182888,0.5964728,0.001136121,0.005845408,0.0264986,0.00008163078,0.1274704,0.1333488],"study_design_scores_gemma":[0.172275,0.02089237,0.08621826,0.001102473,0.0007880167,0.02618445,0.001454901,0.001219472,0.01300797,0.0006867525,0.6750858,0.001084499],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9728506,0.01119349,0.00001042423,0.01193149,0.0009818433,0.0009932137,0.0003897934,0.00004225911,0.001606863],"genre_scores_gemma":[0.9920327,0.002554346,0.00103866,0.0009075599,0.0005928741,0.00003275661,0.00004906952,0.0001243071,0.002667738],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5702884,"threshold_uncertainty_score":0.9999602,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05478826897775532,"score_gpt":0.3568576852568895,"score_spread":0.3020694162791342,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}